FRET-based biosensor moxCRONOS enables quantitative monitoring of macromolecular crowding in organelles and protein

Yurina Nakajima1, Hiroaki Suzuki1, Tamami Miyagi1

  • 1Department of Pharmacology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Journal of Biochemistry
|September 30, 2025
PubMed

Insights

Researchers developed moxCRONOS, a new biosensor to measure macromolecular crowding and protein aggregation. This tool aids in understanding neurodegenerative diseases and screening potential therapies.

Area of Science:

  • Cellular Biology
  • Biophysics
  • Neuroscience

Background:

  • Macromolecular crowding is vital for intracellular processes, and its disruption is linked to neurodegenerative diseases.
  • Current tools for quantifying cellular crowding and protein aggregation are limited.
  • Aberrant liquid-liquid phase separation and protein aggregation are hallmarks of neurodegenerative conditions.

Purpose of the Study:

  • To introduce moxCRONOS, a Förster resonance energy transfer (FRET)-based biosensor for quantitative measurement of macromolecular crowding and protein condensation.
  • To enhance the stability of the CRONOS sensor in oxidative environments for cross-organelle comparisons.
  • To detect aggregation-prone states in dipeptide repeat proteins associated with C9ORF72-linked neurodegeneration.

Main Methods:

  • Development of a Förster resonance energy transfer (FRET)-based biosensor, moxCRONOS.
  • Fusion of moxCRONOS to dipeptide repeat proteins, including glycine-alanine (GA) repeats.
  • Utilizing fluorescence-activated cell sorting (FACS) for sensitive detection of high-FRET populations.
  • Treatment with molecular crowding agents and proteasome inhibitors to validate sensor response.

Main Results:

  • moxCRONOS demonstrates enhanced stability in oxidative environments, enabling comparisons across organelles.
  • The biosensor successfully detects aggregation-prone states in cells expressing GA repeats associated with C9ORF72 neurodegeneration.
  • Fluorescence-activated cell sorting enabled quantitative detection of heterogeneous cell populations with GA aggregates.
  • FRET signal intensity correlated with treatments involving molecular crowding agents or proteasome inhibitors.

Conclusions:

  • moxCRONOS is a stable and versatile biosensor for quantifying macromolecular crowding and pathological protein aggregation.
  • The sensor facilitates direct comparison of crowding levels across different cellular compartments and redox conditions.
  • moxCRONOS shows promise for disease modeling of neurodegenerative conditions and therapeutic screening.